Evidence-graded biotech diligence
Built live from primary records at PubMed, ClinicalTrials.gov, openFDA, Open Targets, ChEMBL and PubChem. Zero black-box predictions: we surface cited evidence, failure modes, and historical analogs.
7 Primary Biomedical Registries. Live Traceability.
Every citation is tied directly to primary records at NLM, ClinicalTrials.gov, FDA, EMBL-EBI, and Open Targets. Defensible diligence for biopharma BD, licensing, and venture teams.
NCBI PubMed, ClinicalTrials.gov, openFDA, Open Targets, ChEMBL, PubChem & the USPTO Open Data Portal.
Zero proprietary black-box data. Every analog and trial outcome links to its primary record.
On-target toxicity, off-target liabilities, PK/PD hurdles, resistance mutations & safety signals.
Traceable failure modes over historical programs
Biotech assets fail for recurring, documented reasons. We cross-reference your candidate against hundreds of terminated and approved analogs to map liabilities early.
Mechanistic contradictions surfaced directly
We synthesize peer-reviewed literature alongside open clinical endpoints to detect unstated gaps, disputed mechanisms, and translational discrepancies.
Four architectural pillars powering diligence
Biotech due diligence doesn't need speculative predictions. Our moat is built on verifiable biological topologies, structured trial outcomes, contradictory evidence extraction, and workflow UX.
Proprietary Therapeutic Graph
Topological graph linking molecular targets, disease pathways, clinical trials, and bioactive entities.
Structured Trial Intelligence
Granular trial registry indexing: endpoints, stratification, and documented historical termination reasons.
Mechanistic Contradiction Engine
Automated semantic detection of conflicting biological assertions and disputed trial claims.
Run a multi-source pass in seconds
Enter a compound or target below to generate a synthesized diligence dossier from PubMed, ClinicalTrials.gov, and openFDA FAERS. (Requires 15 🪙 Tokens)
Biotech assets don't fail in novel ways. They repeat history.
Most diligence memos rely on pitch decks and self-selected peer comparisons without verifiable rationale. Curebiology extracts historical clinical trials, discontinued analogs, and post-marketing safety signals so your team recognizes the real biological failure modes before deploying resources.
Indication workspace (Cancer)
My Overview
Personalized insights for your research journey.
Research
Explore the shape of the indexed literature.
Articles by Subtype
Distribution of articles by disease subtype.
- Loading…
A Vision for Auditable Therapeutic Science
Biopharma decisions should never hinge on unverifiable hype, opaque black-box assertions, or uncorroborated pitch decks. We believe every diligence memorandum, asset appraisal, and clinical strategy must carry an immutable, transparent citation chain directly back to primary scientific records.
Saving Dozens of Hours on Every Memo
By synthesizing historical clinical trial failures and attrition causes instantly, biopharma venture and BD teams bypass weeks of tedious manual literature scouring.
Zero Black-Box Assertions
Every claim, target interaction, and pharmacovigilance alert links directly to open FDA, PubMed, and ChEMBL records so scientific scrutiny remains entirely independent and defensible.
Traceable Open Citations
Every synthesized claim connects directly to open public biomedical records from PubMed, ClinicalTrials.gov, and openFDA that you can inspect and verify.
Token-Linked Access Architecture
All platform features — deep literature searches, diligence passes, deck analyses, and AI research briefings — are linked to flexible token balances tailored for individual researchers and enterprise teams.
Frequently asked questions
Our moat is not prediction. Speculative AI predictions of clinical trial success are notoriously fragile and untestable. Our defensible moat is built on four core capabilities: (1) a proprietary therapeutic graph linking biological targets, disease pathways, and molecular entities; (2) structured trial intelligence capturing granular attrition, recruitment velocity, and endpoints; (3) an automated mechanistic contradiction engine highlighting conflicting literature and registry assertions; and (4) purpose-built scientific workflow UX for candidate comparison, deck auditing, and audit-ready diligence dossiers.
Need custom target evaluation or corporate licensing?
Our team collaborates with pharma business development, venture capital funds, and academic translational centers worldwide.